Abstracts Archive - Page 552 of 2607 - ACR Meeting Abstracts

Abstract Number: 1017 • ACR Convergence 2022
Minimal Important Difference (MID), Minimal Detectable Change (MDC), and Disease Activity Thresholds for Two Novel Composite Instruments (3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of Three Phase 3 Studies
William Tillett¹, Laura Coates², Marijn Vis³, Joseph Merola⁴, Enrique R Soriano⁵, Michelle Perate⁶, May Shawi⁷, Miriam Zimmermann⁸, Emmanouil Rampakakis⁹, Mohamed Sharaf¹⁰, Peter Nash¹¹ and Philip Helliwell¹², ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Erasmus MC Universitair Medisch Centrum, Rotterdam, Netherlands, ⁴Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁹McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ¹⁰Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ¹¹School of Medicine, Griffith University, Sunshine Coast, Australia, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Though continuous composite measures of disease activity for psoriatic arthritis (PsA) assessment exist, abbreviated measures that are more feasible for screening in routine clinical…
Abstract Number: 1020 • ACR Convergence 2022
Screening Tools for Spondyloarthritis in Patients with Psoriasis, IBD, and Uveitis – A Scoping Review
Vartika Kesarwani¹, Stephanie Sinnappan², M. Elaine Husni³, Michael Weisman⁴ and Joerg Ermann⁵, ¹University of Connecticut, Farmington, CT, ²Brigham and Women's Hospital, Boston, MA, ³Cleveland Clinic, Cleveland, OH, ⁴Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Extra-articular manifestations of spondyloarthritis (SpA) may precede the development of articular features. Patients seen in dermatology, gastroenterology, and ophthalmology clinics for psoriasis, IBD, or…
Abstract Number: 1018 • ACR Convergence 2022
Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis: Results from the Ongoing FOREMOST Study
Dafna Gladman¹, Laura Coates², Laure Gossec³, Jacob Aelion⁴, Jitendra Vasandani⁵, Sue Cheng⁶, Lihua Tang⁶, Shauna Jardon⁷, Sven Richter⁶ and Philip J Mease⁸, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Sorbonne Université, Paris, France, ⁴West Tennessee Research Institute, Jackson, TN, ⁵West Texas Clinical Research, Lubbock, TX, ⁶Amgen, Inc., Thousand Oaks, CA, ⁷Amgen Inc., Gilbert, AZ, ⁸Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Oligoarticular psoriatic arthritis (PsA) is commonly reported in early disease. Although fewer joints are involved, there may be significant impact on patients’ (pts) quality…
Abstract Number: 1030 • ACR Convergence 2022
Diagnostic Usefulness of Anti-PPM1A-IgM in Patients with Ankylosing Spondylitis
Yeo jin lee¹, Eun-Ju Lee², Soo Min Ahn², Seokchan Hong², Ji Seon Oh³, Chang Keun Lee², Bin Yoo² and Yong Gil Kim², ¹Asan medical center, Seoul, Republic of Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ³Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Ankylosing spondylitis (AS) has been known to have auto-inflammatory nature, hence, the efficacy of autoantibodies is low. However, studies on autoantibodies are ongoing, with…
Abstract Number: 1029 • ACR Convergence 2022
Virtual Assessment in Axial Spondyloarthritis: Validation of Video Observation of Spinal Metrology
Laura Passalent¹, Sareh Keshavarzi¹, Robert Inman¹ and Nigil Haroon², ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network; University of Toronto, Toronto, ON, Canada
Background/Purpose: A shift to virtual clinical encounters was required because of the COVID-19 pandemic. To date, there have been few studies exploring the utility of…
Abstract Number: 1023 • ACR Convergence 2022
Are We Treating-to-target in Spondyloarthritis (SpA)? A Cross Sectional Analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry
Isaac Cheng¹, Ying Ying Leung², Ho SO¹, Praveena Chiowchanwisawakit³, Stanley Angkodjojo⁴, Muhammad Saeed⁵, Kichul Shin⁶, Han Joo Baek⁷, Mohit Goyal⁸, Muhammad Haroon⁹, Eman Satti¹⁰, Nallasivan Subramanian¹¹, Fariz Yahya¹², Soosan Soroosh¹³, ASAL ADNAN RIDHA¹⁴, Ho Yin Chung¹⁵, James Cheng-Chung WEI¹⁶, Kishimoto Mitsumasa¹⁷ and Lai-shan Tam¹, ¹The Chinese University of Hong Kong, Hong Kong, China, ²Rheumatology Department, Singapore General Hospital, Singapore, Singapore, ³Mahidol University, Bangkok, Thailand, ⁴Sengkang General Hospital / Singhealth, Singapore, Singapore, ⁵Central Park Medical College, Lahore, Pakistan, ⁶Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea, ⁷Gachon University College of Medicine, Inchon, Republic of Korea, ⁸CARE Pain & Arthritis Centre, Udaipur, India, ⁹Doctor, Tralee, Ireland, ¹⁰Hamad Medical Corporation, Doha, Qatar, ¹¹Velammal Medical College Hospital, Velammal, India, ¹²University of Malaya, Kuala Lumpur, Malaysia, ¹³Army University for Medical School, Tehran, Iran, ¹⁴Baghdad Teaching Hospital, Baghdad, Iraq, ¹⁵Chiron Medical, Hong Kong, Hong Kong, ¹⁶Chung Shan Medical University Hospital, Taichung, Taiwan, ¹⁷Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: Data on the extent to which internationally agreed treat-to-target (T2T) recommendations were applied in clinical practice in patients with SpA across the Asia-Pacific region…
Abstract Number: 1022 • ACR Convergence 2022
Validation of the SPARCCRETIC E-Tool for Ensuring Scoring Proficiency of MRI Lesions in Axial Spondyloarthritis
Walter P Maksymowych¹, Anna Hadsbjerg², Mikkel Østergaard³, Raphael Micheroli⁴, Susanne J. Pedersen⁵, Adrian Ciurea⁶, Nora Vladimirova², Michael Nissen⁷, Kristyna Bubova⁸, Stephanie Wichuk⁹, Manouk de Hooge¹⁰, Ashish J Mathew¹¹, Karlo Pintaric¹², Monika gregova¹³, Ziga Snoj¹², Marie Wetterslev¹⁴, Karel Gorican¹⁵, Joel Paschke¹⁶, Iris Eshed¹⁷ and Robert G Lambert⁹, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ³Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ⁴University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, ⁵Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ⁶University Hospital Zurich, Zürich, Switzerland, ⁷Hopitaux Universitaires de Genève, Geneva, Switzerland, ⁸First Faculty of Medicine, Charles University,, Prague, Czech Republic, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Ghent University Hospital, Luxembourg, Luxembourg, ¹¹Rigshospitalet, Copenhagen, Denmark, ¹²Radiology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹³Institue of Rheumatology, Prague, ¹⁴Rigshospitalet, Copenhagen, Glostrup, Denmark, ¹⁵MSK radiology unit, Radiology section – Diagnostic department, Geneva University Hospitals, Geneva, Switzerland, ¹⁶CARE Arthritis LTD, Edmonton, AB, Canada, ¹⁷Sheba Medical Center, Tel Aviv, Israel
Background/Purpose: Quantification of inflammatory and structural lesions in the sacroiliac joints (SIJ) on MRI scans from patients with axial spondyloarthritis (axSpA) has a growing list…
Abstract Number: 1034 • ACR Convergence 2022
Characterization of Non-radiographic Axial Spondyloarthritis Patients and the Burden of Disease in Routine Clinical Practice
Kathryn Starzyk, Pam Kumparatana and roger Meng, OM¹, Inc., Boston, MA
Background/Purpose: Axial spondyloarthritis [AxSpA and particularly non-radiographic (nr)AxSpA] has one of the longest diagnostic delays in rheumatology. Although improving, lack of radiographic evidence of disease…
Abstract Number: 1035 • ACR Convergence 2022
Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies
Philip J Mease¹, William Tillett², Sarah Ohrndorf³, Michelle Perate⁴, Mary Medysky⁵, Miriam Zimmermann⁶, May Shawi⁷, Emmanouil Rampakakis⁸, Paul Bird⁹, Alen Zabotti¹⁰, Atul Deodhar¹¹ and Dafna Gladman¹², ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Scientific Affairs, LLC, Seattle, WA, ⁶Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁹University of New South Wales, Sydney, Australia, ¹⁰Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, ¹¹Oregon Health & Science University, Portland, OR, USA, Portland, OR, ¹²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Evidence on the efficacy of advanced therapies for axial involvement in PsA (axPsA) is scarce, largely due to the lack of a widely accepted…
Abstract Number: 1025 • ACR Convergence 2022
Entheseal Biopsy Approach: An Ultrasound-guided Method for Retrieval of Entheseal Tissue from Psoriatic Arthritis Patients
Maria Gabriella Raimondo¹, Milena Pachowsky¹, Cong Xu¹, Simon Rauber¹, Koray Tascilar¹, Hannah Labinsky², Mario Vogg¹, Mina Saad Aziz Saad¹, David Simon¹, Juergen Rech³, Alina Soare¹, Lars Braeuer⁴, Arnd Kleyer¹, Georg Schett⁵ and Andreas Ramming¹, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³University Clinic Erlangen, Erlangen, Germany, ⁴Institute of Anatomy, Chair II, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany, ⁵Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Enthesitis as hallmark feature of psoriatic arthritis (PsA) has been mostly addressed through clinical assessment and imaging evaluation, such as MRI or musculoskeletal ultrasound.…
Abstract Number: 1033 • ACR Convergence 2022
Risk of Mood Disorders in SpA Patients and Correlations with Disease Activity, Quality of Life and Working Ability: Analysis of a Monocentric Cohort
Cosimo Cigolini¹, Federico Fattorini¹, Linda Carli², Andrea Delle Sedie³, Marta Mosca² and Gabriele Marchetti⁴, ¹Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ²Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, PISA, Italy, ³University of Pisa, Pisa, Pisa, Italy, ⁴University of Pisa, Pisa, Toscana, Italy
Background/Purpose: Spondyloarthropathies (SpA) are chronic inflammatory arthritides, characterized by both peripheral and axial skeletal involvement and some typical extra-articular marks; they tend to associate with…
Abstract Number: 1046 • ACR Convergence 2022
Scleroderma Heart Disease
Mohamed Talaat¹, Vivien Hsu² and Daniel Shindler³, ¹Rutgers Robert Wood Johnson University Hospital, North Brunswick, NJ, ²Rutgers-RWJ Medical School, South Plainfield, NJ, ³Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ
Background/Purpose: Scleroderma heart involvement (SHI) is the 3rd leading cause of death in systemic sclerosis (SSc) [1] following interstitial lung disease (ILD) & pulmonary arterial…
Abstract Number: 1040 • ACR Convergence 2022
Impact of Weight and Sex on Long-term Persistence to Secukinumab Treatment in Patients with Active Psoriatic Arthritis or Ankylosing Spondylitis
Uta Kiltz¹, Petros P. Sfikakis², Nicola Gullick³, ATHINA THEODORIDOU⁴, Anna Kandyli⁵, Jan Brandt-Juergens⁶, Philippe Goupille⁷, Nicola Maiden⁸, Karl Gaffney⁹, Daniel Peterlik¹⁰, Barbara Schulz¹¹, Effie Pournara¹¹ and Piotr Jagiello¹¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ³University Hospital Coventry & Warwickshire; Warwick Medical School, University of Warwick, Coventry, United Kingdom, ⁴Euromedica Geniki Kliniki, General Hospital, Thessaloniki, Greece, ⁵Rheumatology Outpatient Clinic, Iaso General Hospital, Athens, Greece, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Rheumatology department, University Hospital of Tours, Tours, France, ⁸Craigavon Area Hospital, Southern Health & Social Care Trust, Craigavon, United Kingdom, ⁹Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ¹⁰Novartis Pharma GmbH, Nürnberg, Germany, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) has demonstrated a high sustained response rate in patients (pts) with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) across Phase III clinical…
Abstract Number: 1042 • ACR Convergence 2022
Long-term Safety of Ixekizumab in Adult Patients with Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis
Atul Deodhar¹, Andrew Blauvelt², Sergio Schwartzman³, Carlo Salvarani⁴, Meghan Feely⁵, Andris Kronbergs⁵, Nadia Eberhart⁶, Danting Zhu⁵, Elsa Mevel⁵, Thorsten Holzkämper⁵, Eswar Krishnan⁷, Mark Lebwohl⁸, Proton Rahman⁹ and Helena Marzo-Ortega¹⁰, ¹Oregon Health & Science University, Portland, OR, USA, Portland, OR, ²Oregon Medical Research Center, Portland, OR, USA, Portland, OR, ³72nd Street Medical Associates, Scarsdale, NY, ⁴University of Reggio Emilia, Reggio Emilia, Italy, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Vienna, Austria, ⁷Eli Lilly and Company, Carmel, IN, ⁸Icahn School of Medicine at Mount Sinai, New York, NY, ⁹Memorial University, St. John's, NL, Canada, ¹⁰Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom
Background/Purpose: Ixekizumab (IXE) is a high-affinity, monoclonal antibody targeting IL-17A and is approved for the treatment of psoriasis (PsO), psoriatic arthritis (PsA), ankylosing spondylitis (AS),…
Abstract Number: 1038 • ACR Convergence 2022
Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Ankylosing Spondylitis
Arthur Kavanaugh¹, Xenofon Baraliakos², Sheng Gao³, Warner Chen³, Kristen Sweet³, Soumya Chakravarty⁴, Qingxuan Song³, May Shawi⁵, Frank Behrens⁶ and Proton Rahman⁷, ¹University of California San Diego, San Diego, CA, USA, San Diego, CA, ²Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ³Janssen Research and Development, LLC, Spring House, PA, ⁴Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁵Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁶Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁷Memorial University, St. John's, NL, Canada
Background/Purpose: Despite overlapping symptoms, axial psoriatic arthritis (axPsA) and ankylosing spondylitis (AS) may be distinct disorders with differing clinical manifestations, genetic associations, and radiographic findings.1…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].